Organon (MEX:OGN) Total Receivables: MXN24,957 Mil (As of Mar. 2026)


MEX:OGN Organon & Co MEX:OGN
58 GF Score
Price MXN229.00
GF Value MXN267.50
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Organon Total Receivables?

Organon MEX:OGN 58 Total Receivables is MXN24,957 Mil as of Mar. 2026. GuruFocus rates MEX:OGN with a GF Score™ of 58/100 and a GF Value™ of MXN267.50 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Organon's Total Receivables for the quarter that ended in Mar. 2026 was MXN24,957 Mil.

Organon Total Receivables Historical Data

* Premium members only.

The historical data trend for Organon's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organon Total Receivables Chart

Organon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 28,350.35 28,756.60 29,603.09 28,322.04 23,965.59

Organon Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29,807.60 27,942.53 27,222.79 23,965.59 24,957.26
MEX:OGN
58GF Score
Organon & Co MEX:OGN
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organon Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of MXN24,957 Mil mean?
Organon (MEX:OGN) has a Total Receivables of MXN24,957 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Organon and its competitors.
Is Organon's Total Receivables too high?
Organon's current Total Receivables is MXN24,957 Mil. Overall, Organon has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organon's Total Receivables compare to AMRN and SCLX?
Organon's Total Receivables of MXN24,957 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Organon and its competitors. Organon's current Total Receivables is MXN24,957 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (MEX:OGN) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN267.50, compared to a current price of MXN229.00 — trading 14.4% below its estimated fair value. The current Total Receivables is MXN24,957 Mil. Organon's overall GF Score™ is 58/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Organon (MEX:OGN), the current Total Receivables is MXN24,957 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organon (MEX:OGN) Overvalued in 2026?

Based on GuruFocus' analysis, Organon stock appears to be undervalued. The current stock price of MXN229.00 is trading 14.4% below its estimated GF Value™ of MXN267.50. GuruFocus considers Organon to be Modestly Undervalued.

Key valuation signals for MEX:OGN:

  • Total Receivables: MXN24,957 Mil
  • GF Value™: MXN267.50 vs. price of MXN229.00 (14.4% below fair value)
  • GF Score™: 58/100 with 10 warning signs

No single metric tells the full story. See the MEX:OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organon Business Description

Address 30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
58GF Score

Get the complete analysis for MEX:OGN

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN229.00
Price
MXN267.50
GF Value